Research ArticleArticle
Frailty Index to Measure Health Status in People with Systemic Sclerosis
Michael R. Rockwood, Ellen MacDonald, Evelyn Sutton, Kenneth RockwoodCanadian Scleroderma Research Group, Kenneth RockwoodCanadian Scleroderma Research Group and Murray Baron
The Journal of Rheumatology March 2014, jrheum.130182; DOI: https://doi.org/10.3899/jrheum.130182
Michael R. Rockwood
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
Ellen MacDonald
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
Evelyn Sutton
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
Kenneth Rockwood
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
Kenneth Rockwood
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
Murray Baron
From Geriatric Medicine Research; Division of Rheumatology; Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, Halifax, Nova Scotia; and Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is funded by the Canadian Institutes of Health Research (CIHR; grant #FRN 83518), the Scleroderma Society of Canada and its provincial Chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, INOVA Diagnostics Inc. (San Diego, CA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec (FRSQ), the Canadian Arthritis Network (CAN), and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, QC. The CSRG has also received educational grants from Pfizer and Actelion pharmaceuticals. Funds for secondary analysis came from the Fountain Innovation Fund of the Queen Elizabeth II Health Sciences Foundation and by an operating grant to KR from the Canadian Institutes of Health Research MOP-209888. M.R. Rockwood, BEng, Research Analyst; E. MacDonald, Research Assistant, Geriatric Medicine Research, Department of Medicine, Dalhousie University and Capital District Health Authority; E. Sutton, MD, FRCPC Professor of Medicine, Division of Rheumatology, Department of Medicine, Dalhousie University and Capital District Health Authority; K. Rockwood, MD, FRCPC, FRCP Professor of Medicine, Geriatric Medicine Research, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority; M. Baron, MD, Associate Professor of Medicine, Division of Rheumatology, Department of Medicine, McGill University and SMBD-Jewish General Hospital. For a list of CSRG members see Appendix 1. Address correspondence to Prof. Rockwood, Division of Geriatric Medicine, Department of Medicine, Dalhousie University and Capital District Health Authority, 1421-5955 Veterans’ Memorial Lane, Halifax, Nova Scotia, B3H 2E1 Canada. E-mail: Kenneth.Rockwood@dal.ca. Accepted for publication December 13, 2013.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Frailty Index to Measure Health Status in People with Systemic Sclerosis
Michael R. Rockwood, Ellen MacDonald, Evelyn Sutton, Kenneth RockwoodCanadian Scleroderma Research Group, Kenneth RockwoodCanadian Scleroderma Research Group, Murray Baron
The Journal of Rheumatology Mar 2014, jrheum.130182; DOI: 10.3899/jrheum.130182
Frailty Index to Measure Health Status in People with Systemic Sclerosis
Michael R. Rockwood, Ellen MacDonald, Evelyn Sutton, Kenneth RockwoodCanadian Scleroderma Research Group, Kenneth RockwoodCanadian Scleroderma Research Group, Murray Baron
The Journal of Rheumatology Mar 2014, jrheum.130182; DOI: 10.3899/jrheum.130182